Recently, Chen et al. reported that erythroid terminal differentiation was improved in a culture of HSPCs derived from human embryonic stem cells by adding an aryl hydrocarbon receptor antagonist [65], and this represents a less laborious approach that is compatible with SCD disease models. The gene discussed is AHR; the disease is Schnyder corneal dystrophy.